Abstract OBJECTIVE: Levetiracetam has been widely used for childhood epilepsy, but there is no high quality evidence to support its use. This study performed a systematic review to evaluate the effectiveness and safety of levetiracetam therapy for childhood epilepsy. METHODS: The papers related to levetiracetam therapy for childhood epilepsy published up to March, 2009 were retrieved electronically from the PubMed, Embase, the Cochrane Library, Chinese Biomedical Database, Wanfang and Weipu Chinese Journals Full-text Database. The relevant papers on randomized control trials (RCTs) or quasi-RCTs were studied by meta analysis. RESULTS: Two papers that met the inclusion criteria were included. The first paper involved 198 patients, including 108 cases in the levetiracetam therapy group and 97 cases in the placebo group. Seven cases (6.9%) were seizurefree in the levetiracetam therapy group compared with 1 case (1%) in the placebo group (P<0.01) 14 weeks after treatment. Levetiracetam therapy decreased significantly the frequency of seizures compared with the placebo treatment. The second paper involved 39 patients, including 21 cases in the levetiracetam therapy group and 18 cases in the oxcarbazepine therapy group. Nineteen cases (90.5%) were seizure-free in the levetiracetam therapy group compared with 13 cases (72.2%) in the oxcarbazepine therapy group (P=0.410) during a follow-up of 12-24 months. The adverse effects in the levetiracetam therapy group were not significantly different from the placebo and the oxcarbazepine therapy groups. CONCLUSIONS: The current evidence shows that levetiracetam therapy is effective for childhood epilepsy. However, it needs to be proved by the multi-centre, large sample RCTs.［Chin J Contemp Pediatr, 2010, 12 (2):128-131］
［2］Reynolds Eh, ILAE/IBE/WHO Global Campaign“Out of the Shadows”: global and regional developments ［J］. Epilepsia, 2001, 42(8):1094-1100.
［3］Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: where do we go from here? ［J］. Bull World Health Organ, 2001, 79(4):344-351.
［5］Otoul C, Arrigo C, Van Rijckevorsel K, French JA. Metaanalysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy［J］. Clin Neuropharmacol, 2005, 28(2):72-78.
［6］Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, White S, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: A systematic review ［J］. Epilepsy Res, 2001, 46(3):259-270.
［7］Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures［J］. Neurology, 2006, 66(11):1654-60.
［8］Coppola G, Franzoni E, Verrotti A, Garone C, Sarajlija J, Operto FF, et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial［J］. Brain Dev, 2007, 29(5):281-284.
［9］Pina-Garza JE, Nordli DR, Jr, Rating D, Yang H, Schiemann J, Duncan B, et al. Efficacy and safety of levetiracetam oral solution as adjunctive treatment of refractory partial-onset seizures in pediatric epileptic patients aged 1 month to <4 years［J］. Epilepsia, 2007, 48(S6):356.
